The primary outcome of clinical remission at 44 weeks was greater with either of two dose regimens of guselkumab than with placebo, David Rubin, MD, reported as part of his presentation here at
Targeting both the IL-23 circulating in the tissue and the receptor remains to be proven,"but nonetheless seems reasonable," he said. Participants had a mean age of 41 years and a mean disease duration of 7.8 years. The 40% using oral corticosteroids were tapered off during the study. Among the participants who achieved clinical remission, 69% of them also showed complete remission on endoscopy.
"As we get more data from these more selective interleukins, we'll get a better sense of how that plays out" vs other similar agents in development, he added.One or more adverse events were reported by 70% of the higher-dose guselkumab group, 65% of the lower-dose guselkumab group, and 68% of the placebo group.
Source: Healthcare Press (healthcarepress.net)
Ulcerative Colitis (UC) UC - Ulcerative Colitis Remission Inflammatory Bowel Disease IBD - Inflammatory Bowel Disease IBD Biologic Therapy Biologics Colitis Interleukins Psoriatic Arthritis Arthropathic Psoriasis Psoriatic Arthropathy Psa Corticosteroid Taper Stroke Cerebrovascular Accident CVA - Cerebrovascular Accident Corticosteroid Monoclonal Antibody
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: AP - 🏆 728. / 51 Read more »
Source: Mynorthwest - 🏆 438. / 53 Read more »
Source: PsychToday - 🏆 714. / 51 Read more »
Source: sdut - 🏆 5. / 95 Read more »
Source: InsideEVs - 🏆 579. / 51 Read more »
Source: KENS5 - 🏆 608. / 51 Read more »